INTRODUCTION
============

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired pluripotent hematopoietic stem cell (HSC) disorder associated with partial or absolute glycosyl-phosphatidyl inositol-anchored protein (GPI-AP) deficiency \[[@B1][@B2]\]. In PNH, a somatic defect in HSCs, which synthesize glycosyl-phosphatidyl inositol (GPI), results in defective GPI linkage of decay-accelerating factor (DAF) and membrane inhibitor of reactive lysis (MIRL) in red blood cells (RBCs). The lack of cell surface expression of these proteins leads to cell lysis by the complement system and destruction of large numbers of RBCs, resulting in hemoglobinuria \[[@B3][@B4][@B5]\]. The most common cause of PNH is somatic mutations associated with the X-chromosomal gene *PIGA*, which encodes one of the several enzymes required for GPI anchor biosynthesis \[[@B6][@B7]\]. Somatic *PIGA* mutations in PNH patients are manifold, the majority including insertions or deletions involving a single base, such as single base substitution, or several bases.

The clinical manifestation of PNH involves clonal expansion of GPI-AP blood cells, which is controlled by intrinsic and extrinsic factors that affect cell growth and survival \[[@B8]\]. However, little is known about the clonal expansion of GPI-AP deficient HSCs in relation to *PIGA* mutations and blood cell lineage. We investigated PNH clonal proliferation in the three cell lineages, RBCs, granulocytes, and T lymphocytes, by analyzing *PIGA* gene mutations and T-cell receptor (TCR) clonality between PNH/aplastic anemia (AA) and classic PNH.

METHODS
=======

Patients
--------

Peripheral blood samples were collected for routine flow cytometry screening for PNH from 24 patients at Seoul St. Mary\'s Hospital, Seoul, Korea, between January 2010 and April 2012. Samples remaining after the screening test were aliquoted at 200 µL/tube. Two or three microtubes were stored immediately at −20℃ until molecular analysis. Diagnosis was confirmed and assigned according to the guidelines for the diagnosis and management of PNH \[[@B9]\]. At sampling, no patient was actively infected, and no evidence for hereditary bone marrow (BM) failure syndromes was found. All patients provided written informed consent for clinical and molecular analyses. The study protocol was approved by the Institutional Review Board of The Catholic University of Korea, Seoul, Korea (KC12RISE0422).

The patients were classified into two groups based on the presence of cytopenia at diagnosis of PNH: PNH with concomitant AA (PNH/AA, N=12) and classic PNH (N=12). Patients who met at least two of the three peripheral blood cytopenias (Hb level: ≤100 g/L, absolute neutrophil count \[ANC\]: 0.5--1.5×10^9^/L, and platelet count \[PLT\]: 20--100×10^9^/L) were classified as PNH/AA \[[@B10]\]. Patients with clinical evidence of intravascular hemolysis without any evidence of other BM failure were classified as classic PNH. There were significant differences between the groups in ANC and PLT. The number of patients who underwent previous immunosuppressive therapy and/or corticosteroid treatment was significantly higher in the PNH/AA than in the classic PNH group. The percentage of patients who were treated with eculizumab was higher in the classic PNH group, whereas allogeneic hematopoietic stem cell transplantation (HSCT) was performed exclusively in the PNA/AA group ([Table 1](#T1){ref-type="table"}).

Analysis of GPI-AP deficient cells
----------------------------------

GPI-AP deficient granulocytes, T lymphocytes, and RBCs were analyzed by flow cytometry using specific monoclonal antibody cocktails: fluorescent aerolysin reagent (FLAER)-Ax488/CD24-PE for granulocytes, FLAER-Ax488/CD3-PE for T lymphocytes, and CD55-FITC/CD59-PE for RBCs. The FLAER-based flow-cytometric assay is recommended to screen for GPI-AP deficient white blood cells (WBCs) because it has higher sensitivity than that based on other GPI-APs, including CD55, CD59, CD24, and CD14, and can detect small clone sizes in PNH as well as AA or myelodysplastic syndrome \[[@B11][@B12]\].

To analyze GPI-AP deficient granulocytes and T lymphocytes, 5 µL of appropriate monoclonal antibody was added to 0.5×10^6^ WBCs and incubated for 20 minutes at 24℃. After RBCs were lysed using 2 mL of BD fluorescence activated cell sorter (FACS) Lysing Solution (BD Pharmingen, Franklin Lakes, NJ, USA), the cells were washed and analyzed on a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA), according to the manufacturer\'s recommendation. For each tube, a minimum of 50,000 events for granulocytes or T lymphocytes was routinely collected. To analyze GPI-AP deficient RBCs, 20 µL of whole blood was diluted with 3 mL of phosphate-buffered saline (PBS) followed by the addition of 50 µL to one tube, and 5 µL of CD59-FITC and CD55-PE to the second tube. The samples were incubated in the dark for 60 minutes at 24℃ and washed twice with PBS by centrifugation as required to optimize separation of Type I, II, and III GPI-AP deficient RBCs. After washing, the RBC pellet was re-suspended in 0.2 mL of PBS, and 50,000 RBCs were acquired in the list mode.

Granulocytes and lymphocytes were initially selected by forward scatter and side scatter. Each cell lineage was assessed for combined expression of FLAER/CD24 (granulocytes) and FLAER/CD3 (T lymphocytes). The limit of detection (LOD) using FLAER as the most discriminant marker combined with CD24 or CD3 was determined as 0.1%. However, because FLAER affinity seems restricted to certain types of GPI anchors, making it unsuitable for evaluation of RBCs \[[@B13]\], we used both CD55 and CD59 for expression analysis for GPI-AP-deficient RBCs with an LOD of 3%.

Isolation of GPI-AP deficient granulocytes and T lymphocytes for molecular analysis
-----------------------------------------------------------------------------------

Granulocytes were isolated from EDTA-blood samples via standard density gradient separation using a mixture of sodium metrizoate and dextran 500 \[[@B14]\]. T lymphocytes were isolated from EDTA-blood samples using the EasySep Human T Cell Enrichment Kit (STEMCELL Technologies, Vancouver, Canada), according to the manufacturer\'s protocol. GPI-AP deficient granulocytes and T lymphocytes were additionally sorted into the FLAER(−)/CD24 and FLAER(−)/CD24 CD3(+) cell population, respectively, by flow cytometry using BD FACSAria II (BD Biosciences). Genomic DNA was extracted from the sorted GPI-AP deficient granulocytes and T lymphocytes using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany).

*PIGA* mutation analysis
------------------------

Genomic DNA isolated from granulocytes and T lymphocytes was used as a template for amplifying individual exons of *PIGA*, including entire exons and the flanking intron sequences, as described previously \[[@B15]\]. PCR amplicons were bi-directionally sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3130XL Genetic Analyzer (Applied Biosystems). The sequence electropherogram was analyzed using Sequencher Software 4.9 (Gene Codes, Ann Arbor, MI, USA). RefSeq ID: NM_002641.3 for *PIGA* was used for cDNA nucleotide numbering. Mutations were confirmed by sequencing via two or more independent PCRs. Genetic variations were compared with the public sequence databases including a database of single nucleotide polymorphisms (dbSNP, <https://www.ncbi.nlm.nih.gov/snp/>), Exome Aggregation Consortium (ExAc, <http://exac.broadinstitute.org>), 1000 Genomes Project Phase 3 database (1000 Genomes, <http://phase3browser.1000genomes.org/index.html>), and Korean Reference Genome Database (KRGDB, <http://152.99.75.168/KRGDB/>). Pathogenic mutations were predicted using PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>) \[[@B16]\] and PROVEAN (<http://provean.jcvi.org>) \[[@B17]\]. We used numerical peak height data of the Sanger sequencing electropherogram to measure semiquantitative *PIGA* mutation burden \[[@B18]\].

TCR gene rearrangement assay
----------------------------

The TCR gene rearrangement assay was used to evaluate the clonality of GPI-AP deficient T lymphocytes. PCR was conducted on genomic DNA isolated from sorted GPI-AP deficient T lymphocytes using IdentiClone *TCRB*, *TCRG*, and *TCRD* Gene Clonality Assay (Invivoscribe Technologies, San Diego, CA, USA). The full set of reactions for TCR gene arrangements included one targeting *TCRD* (Vδ+Dδ+Jδ), one targeting *TCRG* 2.0 (Vγ+Jγ), and three targeting *TCRB* (*TCRB* Tube A: Vβ+J~β~1/2; *TCRB* Tube B: Vβ+J~β~2; *TCRB* Tube C: Dβ+J~β~1/2). The PCR products were analyzed on an ABI 3130XL Genetic Analyzer with GeneMapper software (Applied Biosystems). Criteria for defining a positive peak in *TCRD* and *TCRB* were as follows: (1) a single prominent positive peak within the valid size range for individual primer pairs and (2) products within the valid size range and with peaks of at least three times the amplitude of the third largest peak in the polyclonal background. The *TCRG* interpretation algorithm provided by the manufacturer was implemented in the worksheet to define peaks as positive for clonality in *TCRG* 2.0: (1) the D(x) value of the suspected clonal peak, as calculated within the locked portion of the worksheet, is ≥0.0419; (2) the relative peak ratio of the suspected clonal peak, compared with the smallest adjacent peak, is ≥4; (3) the relative fluorescence unit (RFU) of the suspected clonal peak is ≥20% of the RFU of the highest peak in that sample. All assays were conducted in duplicate.

Statistical analysis
--------------------

As the laboratory findings were not normally distributed as indicated by Kolmogorov-Smirnov and Shapiro-Wilk tests, continuous variables were summarized as median with range and were compared using the Mann--Whitney U test. Pearson\'s chi-square test was used to compare categorical variables. Spearman\'s correlation was determined to estimate the strength and direction of an association that existed between two continuous variables, and a line of best fit was drawn through the data of two variables in a scatterplot. All tests were two-tailed, and *P*\<0.05 was considered significant. All statistical analyses were conducted using MedCalc 12.7.2 (MedCalc Software, Ostend, Belgium).

RESULTS
=======

GPI-AP deficient cell fraction in blood cell lineages
-----------------------------------------------------

We excluded the patients treated with eculizumab from PNH clone size analysis according to cell lineage because eculizumab promotes the survival of GPI-AP-deficient RBCs compared with that of WBCs or lymphocytes \[[@B19]\]. The GPI-AP deficient cell fraction varied according to patient and cell types. The median GPI-AP deficient cell fraction was the highest in granulocytes followed by RBCs and T lymphocytes. GPI-AP-deficient RBCs were more numerous in classic PNH than in PNH/AA patients (*P*=0.018). The GPI-AP deficient granulocyte fraction correlated strongly with the clonal size of RBCs (r~s~=0.69, *P*=0.015). The GPI-AP deficient RBC fraction correlated moderately with percentage of reticulocyte (r~s~=0.565, *P*=0.004) ([Fig. 1](#F1){ref-type="fig"}).

*PIGA* mutation profiles and mutation burden in blood cell lineages
-------------------------------------------------------------------

Nineteen (79.2%) of the 24 PNH patients carried *PIGA* mutations. Among them, 17 patients carried a single heterozygous mutation, and two patients harbored two heterozygous mutations ([Table 2](#T2){ref-type="table"}). Each *PIGA* mutation was exclusive and commonly occurred in exon 2 (48%, 10/21). The frequencies of deletion, duplication, and base substitution in the *PIGA* gene were 43% (9/21), 19% (4/21), and 38% (8/21), respectively. These mutations led to deleterious effects, including premature terminations (N=13), nonsense mutations (N=3), splicing errors (N=2), and missense mutations (N=3). Among the three missense mutations, p.Arg119Pro and p.Glu120Val were deemed "probably damaging" by PolyPhen-2, with scores of 0.999 and 1.000, respectively, and were expected to be "deleterious" by PROVEAN, with scores of −6.137 and −6.530, respectively. In contrast, p.Ala405Val was considered "benign" by PolyPhen-2 (score 0) and "neutral" by PROVEAN (−0.871). The frequency of these three variants was searched in public sequence databases. p.Ala405Val was registered as a "likely benign allele" (RS201361742) in dbSNP, and its variant frequency was reported as 0.0003/27 in ExAc and 0.0003/1 in 1000 Genomes, but it was not registered in KRGDB.

The incidence of *PIGA* mutation did not differ between PNH/AA and classic PNH. There were no significant differences between patients with and without *PIGA* mutation in blood cell counts, reticulocytes, and GPI-AP deficient cell fractions. Median *PIGA* mutation burden was significantly higher in granulocytes (44%) than in T lymphocytes (19.4%) (*P*=0.004). Interestingly, *PIGA* mutation burden in granulocytes correlated with the GPI-AP deficient fractions of RBCs (*P*=0.023) and granulocytes (*P*=0.049). Similarly, the mutation burden of T lymphocytes correlated with the GPI-AP deficient T lymphocyte fraction (*P*=0.006; [Fig. 2](#F2){ref-type="fig"}).

Association of TCR clonality and *PIGA* mutation
------------------------------------------------

TCR clonality was detected in 19 (79.2%) out of the 24 PNH patients. *TCRB*, *TCRG*, and *TCRD* clonality was detected in 50%, 50%, and 41.7% of the patients, respectively ([Table 3](#T3){ref-type="table"}). Interestingly, *PIGA* mutation burden of T lymphocyte was more frequently detected in patients with clonal rearrangements in any of the TCR genes, compared with those with no TCR rearrangements (*P*=0.015). The *PIGA* mutation burden of T lymphocytes was higher in patients with clonal *TCRB* rearrangement than those with no TCR rearrangements (27.2% vs 8.2%; *P*=0.048; [Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

Individual somatic mutations throughout the coding region of the *PIGA* gene were identified in approximately 80% of our PNH patients. The majority (approximately 48%) of *PIGA* mutations were found on exon 2, which contains nearly a half of the coding region, although mutational hotspots were not observed. Like Nafa et al. \[[@B20]\], we frequently found small deletions or duplications/insertions in *PIGA*, which resulted in a frameshift in the coding region and a shortened, nonfunctional protein, except for the three missense mutations (two in exon 2 and one in exon 6). Although PIGA function is usually abrogated by these mutations, decreased PIGA activity due to missense mutations also induces PNH \[[@B21]\]. Because somatic *PIGA* mutations occur in only one or few HSCs, clonal expansion of these HSCs is necessary to develop PNH.

The mechanisms of clonal expansion have been studied actively to elucidate the pathogenesis of PNH \[[@B6][@B7][@B22]\]. The consensus is that a *PIGA* mutation *per se* is not sufficient to induce clonal expansion; additional clonal selection by extrinsic factors and intrinsic clonal evolution is required \[[@B8]\]. More than 20 genes localized on various autosomes are known to mediate GPI biosynthesis and attachment to proteins, and mutation in those genes also triggers PNH development \[[@B23][@B24][@B25][@B26]\].

Consistent with previous studies, we revealed that *PIGA* mutations originated in a multipotent HSC; consequently, we could detect GPI-AP deficient fractions in all three lineages, including T lymphocytes, by flow cytometry as well as genetic analysis \[[@B27][@B28][@B29]\]. The GPI-AP deficient fractions of blood cell lineages correlated with the *PIGA* mutation burden of the respective cell lineages. The GPI-AP deficient fraction was the highest in granulocytes, followed by RBCs and T lymphocytes. PNH was induced by GPI-AP-deficient RBCs chronically undergoing intravascular hemolysis with a lifespan reduced to 10% compared with that of normal RBCs \[[@B30]\]. By contrast, no evidence of reduced granulocyte lifespan was observed in PNH patients \[[@B31]\]. The GPI-AP deficient RBC fraction correlated moderately with percentage of reticulocyte, a representative marker of RBC proliferation, which suggested that clonal PNH RBCs show higher proliferation than normal RBCs. Patients with classic PNH had a larger GPI-AP-deficient RBC fraction than PNH/AA patients, which demonstrated that clonal PNH RBCs in classic PNH have higher proliferation activity.

Although both the GPI-AP deficient fraction and the *PIGA* mutation burden of T lymphocytes were lower than those of granulocytes, the TCR gene rearrangement assay demonstrated the clone formation capacity of GPI-AP deficient T lymphocytes. A previous study demonstrated that GPI-AP deficient T lymphocytes readily expanded and grew significantly in a T-lymphocyte enrichment culture system \[[@B29]\]. In addition, the correlation between *PIGA* mutation burden and TCR gene rearrangement suggested that *PIGA* mutant T lymphocytes themselves could produce a detectable clonal cell population. The fact that GPI-AP deficient and *PIGA* mutant T lymphocytes were only a minor fraction of lymphocytes in most patients may be explained by the long lifespan of lymphocytes \[[@B32]\] and the relatively lower rate of lymphopoiesis compared with myelopoiesis or erythropoiesis \[[@B33]\].

Potential limitations of this study include no identification of *PIGA* mutations in five patients with definitive GPI-AP deficient cells and no detection of any phenotypic differences between patients with and without *PIGA* mutation, including the development of PNH/AA. Therefore, we could not fully explain the clonal expansion of PNH cells based on *PIGA* mutation alone. Additional factors should be studied.

In conclusion, we revealed the presence of *PIGA* mutations in approximately 80% of PNH patients. The mutations were observed in both granulocytes and T lymphocytes. The PNH clone size varied according to cell lineage, and clonal cells may obtain proliferative potential or gain a survival advantage compared with normal cells.
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![Spearman\'s correlations between GPI-AP deficient fractions of each cell lineage. (A) Correlation between GPI-AP-deficient fraction of RBCs (%) and GPI-AP-deficient fraction of granulocytes (%). (B) Correlation between GPI-AP deficient fraction of RBCs (%) and reticulocytes (%).\
Abbreviations: GPI-AP, glycosyl-phosphatidyl inositol-anchored protein; RBCs, red blood cells.](alm-39-438-g001){#F1}

![Spearman\'s correlations between *PIGA* mutation burden and GPI-AP deficient fractions of the three cell lineages. (A) Correlation between GPI-AP deficient fraction of RBCs (red) and granulocytes (blue) (%) and mutation burden of granulocytes (%). (B) Correlation between GPI-AP deficient fraction of T lymphocytes (%) and mutation burden of T lymphocytes (%).\
Abbreviations: GPI-AP, glycosyl-phosphatidyl inositol-anchored protein; RBCs, red blood cells.](alm-39-438-g002){#F2}

![Comparison of *PIGA* mutation burden and GPI-AP deficient fractions of T lymphocytes according to *TCRB* clonality. (A) *PIGA* mutation burden of T lymphocytes was significantly higher in patients with *TCRB* clonality than in patients without *TCRB* clonality (*P*=0.015). (B) The GPI-AP deficient fraction of T lymphocytes was higher, albeit not significantly, in patients with *TCRB* clonality than in patients without *TCRB* clonality (*P*=0.069).\
Abbreviation: GPI-AP, glycosyl-phosphatidyl inositol-anchored protein.](alm-39-438-g003){#F3}

###### Patient characteristics

![](alm-39-438-i001)

  Characteristic                                          Total (N = 24)      PNH/AA (N = 12)     Classic PNH (N = 12)   *P*
  ------------------------------------------------------- ------------------- ------------------- ---------------------- ----------
  Age (yr), median (range)                                45 (9--66)          37 (9--66)          51 (26--65)            \> 0.050
  Male, N (%)                                             15 (63)             7 (58)              8 (67)                 \> 0.050
  Baseline hematological parameters, median (range)                                                                      
   Hb (g/L)                                               804 (51--122)       84 (51--104)        86 (73--122)           \> 0.050
   ANC (× 10^9^/L)                                        2.1 (0.2--8.0)      1.4 (0.2--4.8)      2.6 (0.9--8.0)         0.017
   PLT (× 10^9^/L)                                        81 (5--319)         56 (5--94)          168 (59--319)          \< 0.001
  Reticulocytes (%)                                       3.8 (0.7--23.1)     3.1 (0.7--11.6)     4.6 (2.4--23.1)        \> 0.050
  LDH fold (× ULN), median (range)                        5.9 (1.1--28.9)     5.9 (1.1--17.6)     5.8 (1.1--28.9)        \> 0.050
  PNH clone size, median (range)                                                                                         
   Granulocytes (%)                                       86.8 (11.9--99.4)   86.1 (22.9--99.4)   88 (11.9--97.8)        \> 0.050
   T lymphocytes (%)                                      9.4 (3--16.7)       8.75 (3.0--16.7)    9.6 (6.6--15.0)        \> 0.050
   RBCs (%)                                               67.6 (3.3--95.9)    55.5 (3.3--88.3)    79.7 (16.1--95.9)      0.018
  *PIGA* mutation, N (%)                                  19 (79)             9 (75)              10 (83)                \> 0.050
   Mutation burden in granulocytes (%), median (range)    44.0 (10.5--92.7)   44.0 (12.7--74.4)   50.0 (10.5--92.7)      \> 0.050
   Mutation burden in T lymphocytes (%), median (range)   19.4 (5.0--45.2)    10.0 (5.0--45.2)    25.0 (12.1--41.5)      \> 0.050
  History of IST, N (%)                                   11 (46)             8 (67)              3 (25)                 0.041
  Treatment for PNH, N (%)                                                                                               
   Corticosteroid use                                     20 (83)             8 (67)              12 (100)               0.028
   Eculizumab use                                         9 (38)              2 (17)              7 (58)                 0.035
   Allogeneic HSCT                                        4 (17)              4 (33)              0 (0)                  0.028

Abbreviations: IST, immunosuppressive therapy; Hb, hemoglobin; ANC, absolute neutrophil count; PLT, platelet count; LDH, lactate dehydrogenase; ULN, upper limit normal; PNH, paroxysmal nocturnal hemoglobinuria; RBCs, red blood cells; HSCT, hematopoietic stem cell transplantation; AA, aplastic anemia.

###### *PIGA* mutation profile in patients with PNH

![](alm-39-438-i002)

  No. Case   cDNA change              Protein change      Location   Effect
  ---------- ------------------------ ------------------- ---------- ----------------
  3          c.82delT                 p.Cys28Valfs\*33    Exon 2     PTC
  5          c.91delC                 p.Arg31Valfs\*30    Exon 2     PTC
  17         c.242delG                p.Pro81Leufs\*14    Exon 2     PTC
  6          c.247delC                p.Leu83Serfs\*12    Exon 2     PTC
  3          c.329dupT                p.Pro111Alafs\*19   Exon 2     PTC
  12         c.356G \> C              p.Arg119Pro         Exon 2     Missense
  19         c.359A \> T              p.Glu120Val         Exon 2     Missense
  9          c.515_585dup71           p.Ala196Profs\*23   Exon 2     PTC
  18         c.536delA                p.Asn179Thrfs\*16   Exon 2     PTC
  21         c.568G \> T              p.Glu190\*          Exon 2     Nonsense
  10         c.791delA                p.Glu266Glyfs\*40   Exon 3     PTC
  7          c.802delA                p.Arg268Glufs\*36   Exon 3     PTC
  1          c.834C \> G              p.Tyr278\*          Exon 3     Nonsense
  8          c.981+1G \> A            Splicing error      Intron 4   Splicing error
  4          c.1188+1delG             Splicing error      Intron 5   Splicing error
  20         c.1214C \> T             p.Ala405Val         Exon 6     Missense
  2          c.1233_1234dupAC         p.Arg412Hisfs\*13   Exon 6     PTC
  13         c.1268_1269dupTA         p.Thr424\*          Exon 6     PTC
  16         c.1311_1312delCC         p.His378\*          Exon 5     PTC
  8          c.1332G \> A             p.Trp444\*          Exon 6     Nonsense
  24         c.1339_1346delCCAGATTC   p.Pro447Tyrfs\*3    Exon 6     PTC

Abbreviations: PNH, paroxysmal nocturnal hemoglobinuria; PTC, premature termination codon.

###### TCR gene rearrangement in GPI-AP deficient T lymphocytes of PNH

![](alm-39-438-i003)

  No. Case   TCRB   TCRB   TCRG   TCRD   TCRD   TCR                  
  ---------- ------ ------ ------ ------ ------ ----- ---- ---- ---- ----
  1          −      −      −      \+     \+     \+    −    −    −    \+
  2          −      −      −      −      −      \+    −    \+   \+   \+
  3          −      −      −      −      −      −     −    −    −    −
  4          −      −      \+     \+     \+     \+    −    \+   \+   \+
  5          −      −      −      −      −      \+    −    \+   \+   \+
  6          \+     −      −      −      \+     −     \+   −    \+   \+
  7          −      \+     −      \+     \+     \+    −    −    −    \+
  8          \+     −      −      −      \+     −     −    −    −    \+
  9          −      −      −      \+     \+     \+    −    −    −    \+
  10         −      −      −      \+     \+     \+    −    −    −    \+
  11         −      −      −      −      −      −     −    −    −    −
  12         −      −      −      \+     \+     −     −    \+   \+   \+
  13         −      −      −      −      −      −     −    \+   \+   \+
  14         −      −      −      −      −      −     −    −    −    −
  15         −      −      −      −      −      −     −    −    −    −
  16         −      −      −      \+     \+     −     −    −    −    \+
  17         −      −      \+     −      \+     \+    \+   \+   \+   \+
  18         −      −      −      −      −      −     \+   −    \+   \+
  19         −      −      −      −      −      −     −    −    −    −
  20         −      −      −      \+     \+     \+    −    −    −    \+
  21         −      −      −      −      −      −     −    \+   \+   \+
  22         −      −      −      −      −      \+    −    −    −    \+
  23         −      −      \+     −      \+     \+    −    −    −    \+
  24         −      −      −      −      −      \+    −    \+   \+   \+

Abbreviations: TCR, T-cell receptor; GPI-AP, glycosylphosphatidylinositol-anchored protein; PNH, paroxysmal nocturnal hemoglobinuria; V, variable gene segment; D, diversity gene segment; J, joining gene segment; +, positive; −, negative.
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